Patient characteristics
| R115777 dose (mg) . | Patient no. . | Age/Sex . | Diagnosis . | Stage of disease . | Cytogenetics . | Poor-risk markers . |
|---|---|---|---|---|---|---|
| 100 | 1 | 59 M | AML, M5 | Relapse 2 | 46 XY | CD34 |
| 2 | 51 M | AML, M1 | Relapse 2 | 46 XY | CD34, 7 | |
| 3 | 68 F | CML-BC | Refractory | 46 XY, Ph- | CD34 | |
| 4 | 75 M | AML, M7 | Refractory | 46 XY | CD34 | |
| 5 | 47 M | AML, M1 | Relapse | 46 XY | CD34 | |
| 6 | 72 M | AML, M1 | New | 46 XY | None | |
| 300 | 7 | 69 M | CML-BC | Refractory | t (9; 22;16) | CD34, 7, 20 |
| 8 | 52 F | ALL, L2 | Refractory | t (9; 22) | CD13 | |
| 9 | 71 M | ALL, L2 | Relapse 1 | No growth | CD13 | |
| 10 | 75 M | AML, M4 | New | 46 XY | CD34 | |
| 11 | 67 M | AML, M7 | New | 47 XY, +8 | CD34 | |
| 600 | 12 | 55 M | AML, M1 (2°) | Relapse | 46 XY, 20q- | CD34, 7, 2 |
| 13 | 65 M | AML, M4 | Refractory | 46 XY | None | |
| 14 | 24 F | ALL, L2 | Relapse 1 | 46 XX | None | |
| 15 | 61 M | AML, M0 | Refractory | t (4;12) | CD34, 7 | |
| 16 | 73 M | AML, M2 | Relapse | inv (18) | CD34 | |
| 17 | 54 F | AML, M4 | Refractory | 47 XX, +15 | CD34 | |
| 18 | 72 F | AML, M1 | Refractory | T (2;7), t (x;1) | CD34 | |
| 19 | 73 M | AML, M1 | New | Not done | Not done | |
| 900 | 20 | 73 M | AML, M1 | Relapse 2 | t (7;14) | CD34, 7 |
| 21 | 60 M | ALL, L2 | Refractory | t (9; 22) | CD33 | |
| 22 | 42 M | AML, M5 | Refractory | No growth | CD34 | |
| 23 | 38 F | CML, BC | Refractory | t (9; 22) | Not done | |
| 24 | 69 M | AML, M2 | New | 46 XY | CD34, 7 | |
| 25 | 60 F | ALL, L2 | New | t (9; 22) | None | |
| 26 | 39 M | AML, M5 | Relapse 1 | inv (11) | None | |
| 27 | 26 F | AML, M4 | Refractory | 45 XX, −7 | CD34, 7, 20 | |
| 28 | 75 F | AML, M0 | Refractory | No growth | CD34 | |
| 29 | 75 M | AML, M0 | Refractory | 46 XY | CD34 | |
| 30 | 77 M | AML, M1 | Refractory | −7q, iso (17) | CD34 | |
| 1200 | 31 | 24 F | AML, M4 | Relapse 2 | 47 XX, +8 | CD34, 7 |
| Subpop t (8; 11) | ||||||
| 32 | 72 M | AML, M4 | Relapse 1 | −1q, der (2) | None | |
| t (p21; ?) | ||||||
| 33 | 59 M | AML, M0 | Relapse 2 | 46 XY | CD34 | |
| 34 | 22 F | ALL, L2 | Relapse 1 | 46 X Y | None |
| R115777 dose (mg) . | Patient no. . | Age/Sex . | Diagnosis . | Stage of disease . | Cytogenetics . | Poor-risk markers . |
|---|---|---|---|---|---|---|
| 100 | 1 | 59 M | AML, M5 | Relapse 2 | 46 XY | CD34 |
| 2 | 51 M | AML, M1 | Relapse 2 | 46 XY | CD34, 7 | |
| 3 | 68 F | CML-BC | Refractory | 46 XY, Ph- | CD34 | |
| 4 | 75 M | AML, M7 | Refractory | 46 XY | CD34 | |
| 5 | 47 M | AML, M1 | Relapse | 46 XY | CD34 | |
| 6 | 72 M | AML, M1 | New | 46 XY | None | |
| 300 | 7 | 69 M | CML-BC | Refractory | t (9; 22;16) | CD34, 7, 20 |
| 8 | 52 F | ALL, L2 | Refractory | t (9; 22) | CD13 | |
| 9 | 71 M | ALL, L2 | Relapse 1 | No growth | CD13 | |
| 10 | 75 M | AML, M4 | New | 46 XY | CD34 | |
| 11 | 67 M | AML, M7 | New | 47 XY, +8 | CD34 | |
| 600 | 12 | 55 M | AML, M1 (2°) | Relapse | 46 XY, 20q- | CD34, 7, 2 |
| 13 | 65 M | AML, M4 | Refractory | 46 XY | None | |
| 14 | 24 F | ALL, L2 | Relapse 1 | 46 XX | None | |
| 15 | 61 M | AML, M0 | Refractory | t (4;12) | CD34, 7 | |
| 16 | 73 M | AML, M2 | Relapse | inv (18) | CD34 | |
| 17 | 54 F | AML, M4 | Refractory | 47 XX, +15 | CD34 | |
| 18 | 72 F | AML, M1 | Refractory | T (2;7), t (x;1) | CD34 | |
| 19 | 73 M | AML, M1 | New | Not done | Not done | |
| 900 | 20 | 73 M | AML, M1 | Relapse 2 | t (7;14) | CD34, 7 |
| 21 | 60 M | ALL, L2 | Refractory | t (9; 22) | CD33 | |
| 22 | 42 M | AML, M5 | Refractory | No growth | CD34 | |
| 23 | 38 F | CML, BC | Refractory | t (9; 22) | Not done | |
| 24 | 69 M | AML, M2 | New | 46 XY | CD34, 7 | |
| 25 | 60 F | ALL, L2 | New | t (9; 22) | None | |
| 26 | 39 M | AML, M5 | Relapse 1 | inv (11) | None | |
| 27 | 26 F | AML, M4 | Refractory | 45 XX, −7 | CD34, 7, 20 | |
| 28 | 75 F | AML, M0 | Refractory | No growth | CD34 | |
| 29 | 75 M | AML, M0 | Refractory | 46 XY | CD34 | |
| 30 | 77 M | AML, M1 | Refractory | −7q, iso (17) | CD34 | |
| 1200 | 31 | 24 F | AML, M4 | Relapse 2 | 47 XX, +8 | CD34, 7 |
| Subpop t (8; 11) | ||||||
| 32 | 72 M | AML, M4 | Relapse 1 | −1q, der (2) | None | |
| t (p21; ?) | ||||||
| 33 | 59 M | AML, M0 | Relapse 2 | 46 XY | CD34 | |
| 34 | 22 F | ALL, L2 | Relapse 1 | 46 X Y | None |
AML indicates acute myelogenous leukemia; CML-BC, chronic myelogenous leukemia in blast crisis; ALL, acute lymphoblastic leukemia.